MedChinaGo
Satri-Cel for Advanced Gastric Cancer: The World's First Solid-Tumour CAR-T
November 11, 2026·Updated November 21, 2026|9 min read

Satri-Cel for Advanced Gastric Cancer: The World's First Solid-Tumour CAR-T

What the trial showed, who qualifies, and what it costs in China

OncologyTreatment GuideCancer TreatmentImmunotherapyCost in ChinaMedical TourismWhy Choose China?

The first CAR-T approved for a solid tumour treats gastric cancer in China for ¥990,000 — what the trial showed, who qualifies, and the honest limits.

The first CAR-T approved for a solid tumor — and it was approved in China

On 22 June 2026, China's drug regulator approved satri-cel (CT041, brand name 恺力美) for adults with CLDN18.2-positive, HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma whose disease has progressed after at least two prior lines of treatment.

It is the first CAR-T cell therapy approved anywhere in the world for a solid tumor. That sentence deserves one clarification, because it is often overstated: cell therapy for solid tumors did not begin here — tumour-infiltrating lymphocyte therapy was approved for melanoma in the United States in 2024. What is new is the CAR-T technology itself crossing from blood cancers into a solid organ cancer, which researchers had been trying and failing to do for roughly a decade.

For a patient with advanced gastric cancer in Korea, Japan, Russia, Latin America or anywhere else where third-line options are exhausted, this matters concretely: there is now a licensed, randomised-trial-backed cell therapy for this disease, and it exists in exactly one country.

This guide explains what satri-cel is, what the trial actually showed, who qualifies, what the treatment involves, and what it costs — including the parts that are less flattering.

Cartoon illustration of a stomach-shaped icon with a small glowing receptor marker on its surface, and a group of engineered immune cells travelling toward it with a soft arrow. Bright flat vector cartoon style, warm clinic colors, clean composition, no text

What satri-cel actually is

CLDN18.2 is a protein found on the surface of specialised cells in the stomach lining. It is not tumour-specific — normal gastric mucosa expresses it too — but in gastric and gastroesophageal junction cancer it is expressed at much higher density, and it is largely hidden from the immune system in other tissues. That combination makes it a usable target rather than a perfect one.

satri-cel is an autologous CAR-T: your own T cells are collected, genetically modified to carry a humanised antibody fragment against CLDN18.2, expanded in a GMP facility, and returned to you. Three design details are worth knowing:

  • The antibody fragment is humanised rather than mouse-derived, which reduces the chance your immune system rejects the engineered cells.
  • The CAR uses a CD28 costimulatory domain with a CD28 transmembrane region — a design associated with faster expansion, chosen deliberately for a disease that progresses quickly.
  • The lymphodepletion regimen before infusion is modified. On top of standard cyclophosphamide and fludarabine, it adds low-dose albumin-bound paclitaxel, intended to help CAR-T cells penetrate the dense stroma around a solid tumour. This is one of the three technical problems the field had to solve before solid-tumour CAR-T worked at all.

The dosing is also unusual for a CAR-T. The recommended dose is 250 × 10⁶ CAR-T cells, and the label allows up to three infusions of that dose — the second and third at least 10–16 and 18–28 weeks after the first, each preceded by a fresh lymphodepletion course, and only if the first infusion was tolerated and the disease had not progressed at the first assessment.

The trial that got it approved

The approval rests on CT041-ST-01, published in The Lancet in 2025 — the first randomised controlled trial of CAR-T therapy in solid tumours anywhere in the world.

The design was 2:1, satri-cel versus the physician's choice of standard third-line therapy (paclitaxel, docetaxel, irinotecan, apatinib, or nivolumab). 156 patients were randomised. Median prior lines was two; about 69% had peritoneal metastasis, a group that usually does very badly.

Endpoint (intention-to-treat) satri-cel Physician's choice
Median progression-free survival 3.25 months 1.77 months
PFS hazard ratio 0.37 (95% CI 0.24–0.56), p<0.0001 —
Median overall survival 7.92 months 5.49 months
OS hazard ratio 0.69 (95% CI 0.46–1.05), one-sided p=0.042 —
18-month overall survival 20% 10%

Among patients who actually received treatment, the gap widens: median PFS 4.37 versus 1.84 months (HR 0.30) and median OS 8.61 versus 5.49 months (HR 0.60). With longer follow-up presented to Chinese payers, the treated population showed a median OS of 9.2 months versus 4.0 months for patients who never received satri-cel (HR 0.29), and objective response was 41% versus 4%, with disease control at 81%.

Reading those numbers honestly

A median progression-free survival of 3.25 months sounds unimpressive next to the lymphoma CAR-T figures of 60% complete responses and years of remission. It is important to understand why, and what it does and does not mean.

The comparison is against a population with no standard of care. Third-line gastric cancer is a setting where chemotherapy extends survival by weeks, objective response sits in single digits, and median survival has historically been under six months. In that context, tripling progression-free survival and doubling the 18-month survival rate is a real, randomised, statistically robust result — and it is the first time any CAR-T has demonstrated one in a solid tumour.

But the absolute numbers are small. Roughly one in five patients was alive at 18 months on satri-cel, versus one in ten on chemotherapy. Most patients still progress. This is a treatment that buys meaningful time for a minority and modest time for most — not a cure, and not close to one.

Sixteen of 104 randomised patients never received an infusion. Their cells were collected, but their disease progressed fast enough during manufacturing that they no longer met criteria for treatment. That is the central engineering limitation of autologous CAR-T in a rapidly progressing cancer, and it is the honest reason the intention-to-treat results look weaker than the treated-patient results. Any centre offering this treatment should be able to tell you how it handles that risk — earlier apheresis, bridging therapy, or prioritised manufacturing slots.

Who qualifies

The approved label is narrow and specific. All of the following must be true:

  • Advanced gastric or gastroesophageal junction adenocarcinoma, confirmed pathologically
  • CLDN18.2-positive: immunohistochemistry intensity 2+ or 3+ in at least 40% of tumour cells
  • HER2-negative — if you are HER2-positive, this product is not approved for you, and trastuzumab-based therapy remains the relevant route
  • At least two prior lines of systemic therapy failed
  • Age 18–75, ECOG performance status 0–1
  • At least one measurable lesion, and life expectancy beyond 12 weeks

Two practical notes. First, the CLDN18.2 threshold matters enormously: in Chinese gastric cancer cohorts, roughly 57% of patients meet the 2+ / ≥40% bar, so testing is not a formality — it decides eligibility. Second, if you have previously received an anti-CLDN18.2 therapy of any kind, expression must be re-tested, because the target can be lost under selective pressure.

Getting the biomarker test right

Most international patients arrive with a pathology report that does not include CLDN18.2 at all, because the test is not routinely ordered outside China, Japan and Korea. It is an immunohistochemistry stain on existing tumour tissue — no new biopsy is usually needed if a block is available.

Ask for a report that states, explicitly:

  1. The antibody clone used (CLDN18.2 assays are not interchangeable)
  2. The intensity score (1+, 2+ or 3+)
  3. The percentage of positive tumour cells
  4. HER2 status on the same or a comparable specimen

A report saying only "CLDN18.2 positive" is not enough to determine eligibility. This is the single most common reason a case review stalls.

Cartoon illustration of a pathology slide with a magnified circular view showing stained cells in different shades, a friendly lab technician pointing at the darkest cells, and a small checklist clipboard beside the microscope. Bright flat vector cartoon style, clean clinic colors, no text

Safety: milder than lymphoma CAR-T, but not mild

The safety profile is genuinely one of satri-cel's strengths — and it is easy to misread the headline number.

Cytokine release syndrome occurred in 95% of treated patients — but almost all of it was grade 1–2. Grade 3 CRS occurred in 4.5%, and there were no grade 4 or 5 cases. For context, grade ≥3 CRS rates of 8–10% are typical for China's approved lymphoma CAR-T products.

There were zero cases of ICANS — immune effector cell-associated neurotoxicity — in the pivotal trial. In lymphoma CAR-T, severe neurotoxicity occurs in roughly 12–19% of patients. Zero is a striking result, and consistent with the biology: the target is not expressed in the central nervous system.

The trade-off is haematological. Grade ≥3 cytopenias were near-universal — decreased lymphocytes in 98%, white cells in 77%, neutrophils in 66% — which means prolonged infection risk, growth-factor support, and transfusion requirements. One treatment-related death occurred, from disseminated intravascular coagulation.

There is also a site-specific consideration nobody should gloss over: this is a treatment for a disease of the stomach wall, in patients who often have peritoneal metastases. Tumour response in the gastric wall can, in principle, carry perforation or bleeding risk. The trial did not report this as a dominant safety signal, but it is a reason treatment belongs at a centre with surgical and endoscopic backup, not at a general oncology ward.

What the eight to ten weeks look like

For an international patient, the pathway runs roughly as follows:

  1. Record review and eligibility confirmation — pathology, CLDN18.2 IHC, HER2 status, imaging, prior treatment lines, organ function
  2. Leukapheresis — one session to collect T cells, typically 3–4 hours
  3. Manufacturing — several weeks; this is the bottleneck, and in a rapidly progressing disease it is where patients are lost
  4. Bridging therapy if needed — low-dose chemotherapy to hold the disease steady while cells are made
  5. Lymphodepletion — the modified cyclophosphamide/fludarabine/albumin-bound paclitaxel regimen, about three days
  6. Infusion and inpatient monitoring — typically 2–3 weeks on a dedicated ward, with CRS management and daily blood counts
  7. First assessment — around one month after infusion; this determines whether re-infusion is offered
  8. Follow-up — through Day 90 and beyond, with the option of second and third infusions at the intervals above

Plan on 2.5 to 3 months in China if you are being evaluated for the full multi-infusion schedule, and 6–8 weeks for the first infusion and its immediate follow-up.

The part most patients underestimate comes before any of this — pathology paperwork, remote review and visa. The patient journey guide breaks it down stage by stage.

What it costs

The list price is ¥990,000 per patient course — about $148,000 at ¥6.67 to the dollar — announced by CARsgen at the time of approval. That is deliberately below the ¥1.20–1.29 million band of China's approved lymphoma CAR-T products, and it is the first time a solid-tumour cell therapy has been priced at all.

That figure is the product. Add apheresis, lymphodepletion, 2–3 weeks of inpatient monitoring, ICU contingency, imaging and follow-up, and the realistic all-in range is $170,000–$210,000 in China.

There is no direct international comparison, because no other country has approved a CAR-T for gastric cancer. The nearest Western benchmark is a different modality entirely — CLDN18.2-targeted antibody therapy, which is approved in some markets for first-line use and costs roughly $6,000–$8,000 per cycle over many cycles. That is not a cheaper version of the same thing; it is a different treatment at a different point in the disease.

One payment detail worth stating plainly: CARsgen has applied to China's commercial innovative-drug insurance list, and domestic patients with qualifying supplemental coverage may see out-of-pocket costs fall substantially. International self-pay patients do not qualify for these schemes. The list price is the price.

Why this can only be done in China right now

Three reasons, in order of importance:

Approval. No regulator outside China has licensed a CLDN18.2 CAR-T. There is no equivalent to travel for elsewhere, at any price.

Volume. China records roughly 358,700 new gastric cancer cases a year, and the third-line population eligible for this product is estimated at around 13,000 annually. That case volume is what makes a commercial CAR-T programme for gastric cancer viable in the first place.

Centres. CARsgen has published a list of 64 certified treatment centres for satri-cel, and is concentrating commercial launch on roughly 100 leading cancer hospitals. Certification is not a formality: CLDN18.2 testing, the modified lymphodepletion regimen and gastric-specific complication management are not standard capabilities in every haematology unit.

Cartoon illustration of a map of China with glowing hospital icons connected by soft dotted lines to a central treatment hub, and a small patient figure with a suitcase standing at the hub entrance. Bright flat vector cartoon style, clean and warm, no text

The honest caveats

This is a third-line treatment with modest absolute benefit. If your oncologist at home still has an effective standard option, that option comes first. satri-cel is for the point where the standard options are gone.

Manufacturing failure is a real risk. Sixteen of 104 randomised patients never got their cells. In a fast-moving cancer, a four-week manufacturing window is a clinical vulnerability, not a logistical detail.

Nobody knows the long-term picture yet. The approval is based on a trial with median follow-up under two years. Durability beyond that, the value of second and third infusions, and what to do at progression after satri-cel are all open questions.

The label is a label. Off-label use in pancreatic cancer, in earlier lines, or in combination with other agents is being studied in China, but it is not approved, and it carries trial-grade uncertainty about both benefit and cost.

Getting started

The practical first step is a CLDN18.2 immunohistochemistry report with intensity and percentage, plus HER2 status, pathology, imaging and a full treatment history. Most patients who are told "you may be eligible" turn out to need that stain ordered before anything else can be decided.

MedChinaGo's CAR-T programme reviews gastric cancer records against the current approved label, coordinates CLDN18.2 re-testing where tissue is available, and arranges treatment at certified centres with dedicated CAR-T wards, gastric surgery and endoscopy backup, and oncology-trained interpreters from record review through Day 90 follow-up. Learn more about CAR-T therapy in China — or, if you are still deciding between treatment types, read our comparison of CAR-T, transplant and chemotherapy.

Frequently Asked Questions

Author

M

MedChinaGo Medical Team

Medical Tourism Specialists

https://www.chinamedicaltrips.com/about

This information is for educational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider for personal medical decisions.

Ready to Start Your Medical Journey?

Contact us today for a free consultation and personalized treatment plan

Free Consultation